Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment

Introduction: Frontal alpha asymmetry (FAA) is a proposed prognostic biomarker in major depressive disorder (MDD), conventionally acquired with electroencephalography (EEG). Although small studies attributed trait-like properties to FAA, a larger sample is needed to reliably asses this characteristi...

Full description

Bibliographic Details
Main Authors: Nikita van der Vinne, Madelon A. Vollebregt, Michel J.A.M. van Putten, Martijn Arns
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:NeuroImage: Clinical
Online Access:http://www.sciencedirect.com/science/article/pii/S2213158219304036
id doaj-3615f181d812428f9c0cfadb06d367c7
record_format Article
spelling doaj-3615f181d812428f9c0cfadb06d367c72020-11-25T00:43:24ZengElsevierNeuroImage: Clinical2213-15822019-01-0124Stability of frontal alpha asymmetry in depressed patients during antidepressant treatmentNikita van der Vinne0Madelon A. Vollebregt1Michel J.A.M. van Putten2Martijn Arns3Research Institute Brainclinics, Nijmegen, The Netherlands; Synaeda Psycho Medisch Centrum, Leeuwarden, The Netherlands; Department of Clinical Neurophysiology, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Corresponding author.Research Institute Brainclinics, Nijmegen, The Netherlands; Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The NetherlandsDepartment of Clinical Neurophysiology, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Department of Clinical Neurophysiology and Neurology, Medisch Spectrum Twente, Enschede, The NetherlandsResearch Institute Brainclinics, Nijmegen, The Netherlands; Department of Experimental Psychology, Utrecht University, Utrecht, The NetherlandsIntroduction: Frontal alpha asymmetry (FAA) is a proposed prognostic biomarker in major depressive disorder (MDD), conventionally acquired with electroencephalography (EEG). Although small studies attributed trait-like properties to FAA, a larger sample is needed to reliably asses this characteristic. Furthermore, to use FAA to predict treatment response, determining its stability, including the potential dependency on depressive state or medication, is essential. Methods: In the international Study to Predict Optimized Treatment in Depression (iSPOT-D), a multi-center, randomized, prospective open-label trial, 1008 MDD participants were randomized to treatment with escitalopram, sertraline or venlafaxine-extended release. Treatment response was established eight weeks after treatment initiation and resting state EEG was measured both at baseline and after eight weeks (n = 453). Results: FAA did not change significantly after eight weeks of treatment (n = 453, p = .234), nor did we find associations with age, sex, depression severity, or change in depression severity. After randomizing females to escitalopram or sertraline, for whom treatment response could be predicted in an earlier study, FAA after eight weeks resulted in equivalent response prediction as baseline FAA (one tailed p = .028). Conclusion: We demonstrate that FAA is a stable trait, robust to time, state and pharmacological status. This confirms FAA stability. Furthermore, as prediction of treatment response is irrespective of moment of measurement and use of medication, FAA can be used as a state-invariant prognostic biomarker with promise to optimize MDD treatments. Keywords: Frontal alpha asymmetry, Major depressive disorder, Electroencephalogram, Trait, Personalized medicinehttp://www.sciencedirect.com/science/article/pii/S2213158219304036
collection DOAJ
language English
format Article
sources DOAJ
author Nikita van der Vinne
Madelon A. Vollebregt
Michel J.A.M. van Putten
Martijn Arns
spellingShingle Nikita van der Vinne
Madelon A. Vollebregt
Michel J.A.M. van Putten
Martijn Arns
Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
NeuroImage: Clinical
author_facet Nikita van der Vinne
Madelon A. Vollebregt
Michel J.A.M. van Putten
Martijn Arns
author_sort Nikita van der Vinne
title Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
title_short Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
title_full Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
title_fullStr Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
title_full_unstemmed Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
title_sort stability of frontal alpha asymmetry in depressed patients during antidepressant treatment
publisher Elsevier
series NeuroImage: Clinical
issn 2213-1582
publishDate 2019-01-01
description Introduction: Frontal alpha asymmetry (FAA) is a proposed prognostic biomarker in major depressive disorder (MDD), conventionally acquired with electroencephalography (EEG). Although small studies attributed trait-like properties to FAA, a larger sample is needed to reliably asses this characteristic. Furthermore, to use FAA to predict treatment response, determining its stability, including the potential dependency on depressive state or medication, is essential. Methods: In the international Study to Predict Optimized Treatment in Depression (iSPOT-D), a multi-center, randomized, prospective open-label trial, 1008 MDD participants were randomized to treatment with escitalopram, sertraline or venlafaxine-extended release. Treatment response was established eight weeks after treatment initiation and resting state EEG was measured both at baseline and after eight weeks (n = 453). Results: FAA did not change significantly after eight weeks of treatment (n = 453, p = .234), nor did we find associations with age, sex, depression severity, or change in depression severity. After randomizing females to escitalopram or sertraline, for whom treatment response could be predicted in an earlier study, FAA after eight weeks resulted in equivalent response prediction as baseline FAA (one tailed p = .028). Conclusion: We demonstrate that FAA is a stable trait, robust to time, state and pharmacological status. This confirms FAA stability. Furthermore, as prediction of treatment response is irrespective of moment of measurement and use of medication, FAA can be used as a state-invariant prognostic biomarker with promise to optimize MDD treatments. Keywords: Frontal alpha asymmetry, Major depressive disorder, Electroencephalogram, Trait, Personalized medicine
url http://www.sciencedirect.com/science/article/pii/S2213158219304036
work_keys_str_mv AT nikitavandervinne stabilityoffrontalalphaasymmetryindepressedpatientsduringantidepressanttreatment
AT madelonavollebregt stabilityoffrontalalphaasymmetryindepressedpatientsduringantidepressanttreatment
AT micheljamvanputten stabilityoffrontalalphaasymmetryindepressedpatientsduringantidepressanttreatment
AT martijnarns stabilityoffrontalalphaasymmetryindepressedpatientsduringantidepressanttreatment
_version_ 1725278604115312640